News ReleaseView printer-friendly version
Quidel to Present at the UBS 2007 Global Life Sciences Conference
SAN DIEGO--(BUSINESS WIRE)--Sept. 19, 2007--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced that it will present at the UBS 2007 Global Life Sciences Conference to be held at the Grand Hyatt Hotel in New York on September 24-27, 2007.
Caren Mason, president and chief executive officer, will present on Tuesday, September 25, 2007 at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). Investors may access a live audio webcast via the Investor Information section of the Company's Web site at www.quidel.com. A replay of the presentation and Q&A will be available for 14 days following the conference at the above Web address.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information visit www.quidel.com, www.colorectal-test.com or www.flutest.com.
John Radak, Chief Financial Officer
Lippert/Heilshorn & Associates
Don Markley or Bruce Voss
SOURCE: Quidel Corporation